Jane Henderson Sells 15,416 Shares of Voyager Therapeutics Inc (VYGR) Stock

Voyager Therapeutics Inc (NASDAQ:VYGR) CFO Jane Henderson sold 15,416 shares of the stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $22.15, for a total value of $341,464.40. Following the transaction, the chief financial officer now directly owns 15,416 shares of the company’s stock, valued at $341,464.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jane Henderson also recently made the following trade(s):

  • On Monday, March 19th, Jane Henderson sold 17,316 shares of Voyager Therapeutics stock. The shares were sold at an average price of $22.11, for a total value of $382,856.76.

Voyager Therapeutics Inc (NASDAQ VYGR) traded up $0.12 on Tuesday, hitting $21.18. The stock had a trading volume of 481,258 shares, compared to its average volume of 455,107. Voyager Therapeutics Inc has a 52 week low of $8.10 and a 52 week high of $31.91. The firm has a market capitalization of $702.75, a PE ratio of -7.93 and a beta of 2.37.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Wednesday, March 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.32. Voyager Therapeutics had a negative return on equity of 63.18% and a negative net margin of 697.03%. The company had revenue of $6.35 million during the quarter, compared to analysts’ expectations of $5.81 million. equities analysts forecast that Voyager Therapeutics Inc will post -2.54 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its position in shares of Voyager Therapeutics by 8.9% in the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock valued at $153,000 after buying an additional 1,399 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of Voyager Therapeutics by 8.4% in the second quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock valued at $231,000 after buying an additional 2,000 shares during the last quarter. Thompson Davis & CO. Inc. lifted its position in shares of Voyager Therapeutics by 67.7% in the fourth quarter. Thompson Davis & CO. Inc. now owns 7,485 shares of the company’s stock valued at $124,000 after buying an additional 3,021 shares during the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of Voyager Therapeutics by 11.8% in the second quarter. TIAA CREF Investment Management LLC now owns 37,295 shares of the company’s stock valued at $334,000 after buying an additional 3,939 shares during the last quarter. Finally, Teachers Advisors LLC lifted its position in shares of Voyager Therapeutics by 24.7% in the second quarter. Teachers Advisors LLC now owns 25,685 shares of the company’s stock valued at $230,000 after buying an additional 5,081 shares during the last quarter. 80.03% of the stock is owned by institutional investors.

VYGR has been the subject of several recent research reports. Zacks Investment Research raised Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research report on Friday. Wedbush increased their price target on Voyager Therapeutics from $22.00 to $29.00 and gave the company an “outperform” rating in a research report on Wednesday, February 21st. BTIG Research initiated coverage on Voyager Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $32.00 price target for the company. Canaccord Genuity set a $35.00 price target on Voyager Therapeutics and gave the company a “buy” rating in a research report on Wednesday, March 14th. Finally, BidaskClub raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, February 24th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $29.73.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2018/03/20/jane-henderson-sells-15416-shares-of-voyager-therapeutics-inc-vygr-stock.html.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Insider Buying and Selling by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply